Bank of England chief urges banks to show restraint on bonuses; global stocks recover – business live | Business
We’re very pleased with these data, which confirm our strong science and the benefits of our Covid-19 vaccine. The Sanofi-GSK vaccine demonstrates a universal ability to boost all platforms and across all ages.
We also observed robust efficacy of the vaccine as a primary series in today’s challenging epidemiological environment. No other global Phase 3 efficacy study has been undertaken during this period with so many variants of concern, including Omicron, and these efficacy data are similar to the recent clinical data from authorised vaccines.
